<DOC>
	<DOCNO>NCT01519674</DOCNO>
	<brief_summary>This trial conduct Asia , Europe , Oceania South America . The aim clinical trial generate data demonstrate intensify diabetes treatment use BIAsp 30 ( biphasic insulin aspart 30 ) add substitute BIAsp 30 sitagliptin various regimen type 2 patient inadequately control sitagliptin metformin ( without oral anti-diabetic drug ( OADs ) ) . The trial conduct phase 4 trial majority participate country . However , country trial conduct phase 3b .</brief_summary>
	<brief_title>Treatment Intensification With Biphasic Insulin Aspart 30 Subjects With Type 2 Diabetes Inadequately Controlled Sitagliptin Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Diagnosed type 2 diabetes minimum 6 month prior screen ( Visit 1 ) Stable treatment total daily dose least 1000 mg metformin ( without additional oral antidiabetic drug ( OADs ) treatment ) . The metformin dose must unchanged least 3 month prior screen ( Visit 1 ) Stable treatment total daily dose least 100 mg sitagliptin . The sitagliptin dose must unchanged least 3 month prior screen ( Visit 1 ) Subject insulinna√Øve ( never previously treat insulin ) . ( However , short term insulin use due intermittent illness 14 day insulin treatment gestational diabetes allow ) HbA1c ( glycosylated haemoglobin ) 7.0 10.0 % ( 5386 mmol/mol ) ( inclusive ) central laboratory analysis demonstrate inadequate control sitagliptin metformin ( without OADs ) Body Mass Index ( BMI ) equal 40.0 kg/m^2 Able willing eat least 2 meal ( breakfast dinner ) every day trial Treatment thiazolidinedione ( TZD ) glucagonlikepeptide1 ( GLP1 ) receptor agonist within last 3 month prior screen ( Visit 1 ) Cardiac disease within last 6 month prior screen ( Visit 1 ) , define : decompensated heart failure New York Heart Association ( NYHA ) class III IV ; unstable angina pectoris ; myocardial infarction Severe hypertension , systolic blood pressure equal 180 mm Hg diastolic blood pressure equal 100 mm Hg , 5 minute rest sit position use mean value 3 measurement screen ( Visit 1 ) Anticipated change dose systemic treatment product , trial physician 's opinion could interfere glucose metabolism ( e.g. , systemic corticosteroid ) Clinically significant disease ( except condition associate type 2 diabetes ) , trial physician 's opinion may confound result trial pose additional risk administer trial product ( ) Impaired hepatic function indicate aspartate aminotransferase ( ASAT ) alanine aminotransferase ( ALAT ) 2.5 time upper normal range , accord central laboratory reference range Impaired renal function indicate serum creatinine level equal 133 micromol/L ( 1.5 mg/dL ) males equal 124 micromol/L ( 1.4 mg/dL ) females estimate creatinine clearance 60 mL/min , base Cockroft &amp; Gault formula accord local practise metformin use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>